--- title: "Fridge-free tetanus-diphtheria vaccine succeeds in first human trial" publication: "MediaBias News" url: "https://mediabias.news/tech/fridge-free-tetanus-diphtheria-vaccine-succeeds-in-first-human-trial" api: "https://mediabias.news/api/v1/stories/fridge-free-tetanus-diphtheria-vaccine-succeeds-in-first-human-trial" markdown: "https://mediabias.news/tech/fridge-free-tetanus-diphtheria-vaccine-succeeds-in-first-human-trial.md" audio: "https://mediabias.news/api/audio/fridge-free-tetanus-diphtheria-vaccine-succeeds-in-first-human-trial" category: "Science & Tech" area: "United Kingdom" published: "2026-08-06T20:46:07.980Z" source_reported: "2026-08-06T15:40:02.000Z" updated: "2026-08-06T20:46:07.980Z" trust_score: 86 critic_score: 80 hype_score: 18 assessment_type: "coverage-and-source-reporting-analysis" fact_check_status: "not-performed" coverage_measured: "2026-08-08T00:30:07.879777+00:00" --- # Fridge-free tetanus-diphtheria vaccine succeeds in first human trial *Phase 1 results show SPVX02 remains effective after two years at 30°C, with no serious side effects* **Scores for the source reporting** (0-100, assessing the original journalism this article was written from, not this write-up): - Trust 86 of 100, higher is better. Trust high (86) due to named researchers, published journal, independent outlets, and specific figures with sources. - Craft 80 of 100, higher is better. Critic score 80 reflects clear explanation of relevance, multiple quotes, specific data, future steps, but includes a press‑release source. - Hype 18 of 100, lower is better. Hype low (18); language is measured and headlines match the factual content. Scored by MediaBias News; method at https://mediabias.news/methodology. **The short version** - The phase 1 trial of SPVX02, a fridge-free tetanus-diphtheria vaccine, enrolled 60 healthy adults in the UK. - All participants achieved protective antibody levels against tetanus and diphtheria by day 28, with no vaccine-related serious adverse events reported. - The vaccine remained stable and fully potent after storage at up to 30°C for at least two years, according to the study published in *eClinicalMedicine*. - A phase 2b trial is now underway to further assess the vaccine in a larger group of participants. A tetanus-diphtheria vaccine that does not require refrigeration has shown promising results in its first human trial. The vaccine, SPVX02, was developed by UK-based biotech company Stablepharma using its StablevaX technology. It is a reformulated version of a licensed vaccine, designed to remain stable at temperatures up to 30°C for at least two years. The phase 1 trial, led by the University of Southampton and University Hospital Southampton NHS Foundation Trust, enrolled 60 healthy adults. By day 28 after vaccination, all participants who received SPVX02 achieved protective antibody levels against both tetanus and diphtheria. The study, published in *eClinicalMedicine*, reported no vaccine-related serious adverse events. The vaccine also remained stable after three cycles of extreme temperature fluctuations between -20°C and +40°C. The World Health Organization has previously stated that a significant portion of vaccines are wasted globally each year due to temperature changes during storage and transport. The trial’s findings suggest that fridge-free vaccines could reduce this waste and improve access in remote or conflict-affected regions where maintaining a cold chain is difficult. ## What the coverage left out No left- or right-rated outlet ran this story. The omission is a finding: the story was covered exclusively by centre-rated and unrated outlets. None of the digests or reports specified the exact percentage of vaccines wasted globally, though the World Health Organization’s estimate was referenced in the full reports from Medical Xpress and EIN Presswire. ## Who covered it Shares of the 4 covering outlets with a published leaning rating: - Left: 0% (0) - Centre: 100% (4) - Right: 0% (0) 7 of 11 covering outlets carried no usable leaning rating and were excluded from those percentages. Coverage measured 2026-08-08T00:30:07.879777+00:00. **Coverage watch:** developing. Checked 113 times; 0 checks found a material change. Most recently checked 2026-08-08T01:15:06.571Z. ## How the sides framed it ### Left No separate framing summary. ### Centre - The three centre-rated reports, Medical Xpress, *The BMJ*, and BBC News, led on the vaccine’s potential to address cold-chain failures and improve global access. Medical Xpress quoted Professor Saul Faust, who led the trial, saying the vaccine could "transform the way vaccines are stored and delivered around the world" if larger studies confirm the findings. *The BMJ* described the development as a potential "game changer" for global health, particularly in resource-poor settings. - BBC News focused on the broader implications, framing the trial as a solution to vaccine wastage. None of the centre-rated digests mentioned the specific percentage of vaccines wasted globally, though Medical Xpress and *The BMJ* referenced the issue in general terms. All three reports highlighted the vaccine’s stability at 30°C and its potential to reduce reliance on refrigeration. ### Right No separate framing summary. ## Factuality profile of the covering outlets These are published factuality ratings of the outlets, not a verdict on whether this story or its claims are true. - veryLow: 1 - high: 1 - unknown: 5 - veryHigh: 4 ## Verification scope This page compares coverage and scores the source reporting. It is not a ClaimReview verdict on whether the underlying event or claim is true. ## Original reporting this was written from - [European Medical Journal](https://emjreviews.com/general-healthcare/news/successful-trials-of-fridge-free-vaccines-to-boost-global-distribution) — Successful Trials of Fridge-Free Vaccines To Boost Global Distribution - [cedarnews.net](https://cedarnews.net/bbc/940630/%d9%84%d9%82%d8%a7%d8%ad%d8%a7%d8%aa-%d9%84%d8%a7-%d8%aa%d8%ad%d8%aa%d8%a7%d8%ac-%d8%a5%d9%84%d9%89-%d8%a7%d9%84%d8%aa%d8%a8%d8%b1%d9%8a%d8%af-%d8%a7%d8%a8%d8%aa%d9%83%d8%a7%d8%b1-%d9%82%d8%af-%d9%8a) — Vaccines that Don't Require Refrigeration: an Innovation that Could Reduce the Waste of Half of All Vaccines Globally - [Medical Xpress](https://medicalxpress.com/news/2026-08-fridge-free-tetanus-diphtheria-vaccine.html) — Fridge-free tetanus-diphtheria vaccine shows promise of reaching millions worldwide - [nihr.ac.uk](https://southamptoncrf.nihr.ac.uk/post/fridge-free-vaccine-shows-promise-for-reaching-millions-more-people-worldwide) — Fridge-free vaccine shows promise for reaching millions more people worldwide - [The BMJ](https://bmj.com/content/394/bmj-2026-100517) — “Fridge-free” vaccine for tetanus-diphtheria shows promise in first human trial - [BBC News](https://bbc.com/news/articles/ce85qe8j0nzo) — Half of vaccines are binned - this plant could change that - [Science Media Centre](https://sciencemediacentre.org/phase-1-results-from-fridge-free-tetanus-diphtheria-vaccine) — Phase 1 results from ‘fridge-free’ tetanus-diphtheria vaccine - [uhs.nhs.uk](https://uhs.nhs.uk/whats-new/press-releases/fridge-free-vaccine-shows-promise-for-reaching-millions-more-people-worldwide) — Fridge-free vaccine shows promise for reaching millions more people worldwide - [nursinginpractice.com](https://nursinginpractice.com/clinical/vaccination-and-infection/fridge-free-vaccine-trial-shows-encouraging-results) — Fridge-free vaccine trial shows ‘encouraging results’ - [The Lancet](https://thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00369-X/fulltext) — Safety, tolerability, and immunogenicity of SPVX02, a room temperature-stabilised tetanus-diphtheria vaccine, compared to two established tetanus-diphtheria booster vaccines: a multicentre, single-blind, randomised, first-in-human phase 1 trial in the UK - [EIN Presswire](https://einpresswire.com/article/931875499/the-lancet-s-eclinicalmedicine-publishes-phase-i-data-for-spvx02-a-fridge-free-td-vaccine-stable-for-24-months-at-30-c) — The Lancet’s eClinicalMedicine Publishes Phase I Data for SPVX02, a Fridge-free Td Vaccine Stable for 24 Months at 30°C ## Questions **What is SPVX02?** SPVX02 is a fridge-free tetanus-diphtheria vaccine developed by UK-based biotech company Stablepharma. It is designed to remain stable at temperatures up to 30°C for at least two years, addressing cold-chain failures that lead to vaccine wastage globally. **What were the results of the phase 1 trial?** The phase 1 trial enrolled 60 healthy adults and found that all participants achieved protective antibody levels against tetanus and diphtheria by day 28. No vaccine-related serious adverse events were reported, and the vaccine remained stable after storage at 30°C for two years. **Why is a fridge-free vaccine significant?** A fridge-free vaccine could reduce vaccine wastage caused by temperature changes during storage and transport. It could also improve access in remote or conflict-affected regions where maintaining a cold chain is difficult, potentially saving millions of doses annually. --- MediaBias News — https://mediabias.news. Reproduced from https://mediabias.news/tech/fridge-free-tetanus-diphtheria-vaccine-succeeds-in-first-human-trial. Please cite as: MediaBias News, "Fridge-free tetanus-diphtheria vaccine succeeds in first human trial", https://mediabias.news/tech/fridge-free-tetanus-diphtheria-vaccine-succeeds-in-first-human-trial